Churchill Downs Incorporated 2020 Third Quarter Financial Results Conference Call Invitation

Written by Customer Service on October 14, 2020. Posted in Public Companies.

LOUISVILLE, Ky., Oct. 14, 2020 (GLOBE NEWSWIRE) — Churchill Downs Incorporated (“CDI” or “the Company”) announced today that the Company will release third quarter 2020 financial results after the market closes on Wednesday, October 28, 2020, and host a related conference call to discuss the quarter on Thursday, October 29, 2020, at 8 a.m. ET.Investors and other interested parties may listen to the teleconference by accessing the online, real-time webcast of the call at http://ir.churchilldownsincorporated.com/events.cfm or by calling (877) 372-0878 and entering the conference ID number 5858624 at least 10 minutes before the appointed time. International callers should dial (253) 237-1169. An online replay of the call will be available at http://ir.churchilldownsincorporated.com/events.cfm by noon ET on Thursday, October 29, 2020.A...

Consumer Portfolio Acknowledges Receipt of Indication of Interest from Third Party

Written by Customer Service on October 14, 2020. Posted in Public Companies.

LAS VEGAS, Nevada, Oct. 14, 2020 (GLOBE NEWSWIRE) — Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that it had received on October 7, 2020 a non-binding, unsolicited indication of interest to acquire the Company from Auto Experience Inc. (“AEI”). Other than a three-page May letter from AEI delivered to the Company’s CFO, and rejected at that time, neither management nor the Board of Directors of the Company have had any discussions with AEI regarding a purchase of the Company.Following delivery of the October 7 indication of interest, AEI issued a press release announcing its interest in acquiring the Company in what AEI described as an all-cash transaction valued at $135 million. CPS believes that the press release mischaracterizes the indicated terms set forth in AEI’s proposal, as the...

Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Written by Customer Service on October 14, 2020. Posted in Public Companies.

Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that preclinical data from its collaboration with The University of Texas MD Anderson Cancer Center and Washington University School of Medicine will be presented in an oral presentation at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held virtually on November 9-14, 2020.Details of the oral presentation:Title: AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignanciesAbstract ID: 349Authors: Lucila Kerbauy, Nancy D. Marin, Mecit Kaplan, Pinaki Banerjee, Melissa Berrien-Elliott, Michelle Becker-Hapak, Rafet Basar, Mark Foster, Luciana Garcia Melo, Carly Neal,...

Genocea Announces Upcoming Data Presentations at Virtual SITC 2020

Written by Customer Service on October 14, 2020. Posted in Public Companies.

Will showcase clinical and immune responses from the ongoing GEN-009 Phase 1/2a trialWill provide a detailed introduction to GEN-011, an adoptive T cell therapy designed to improve upon the limitations of TIL and TCR therapiesWill share new insights on the utility of InhibigensTMas identified by ATLASTMto inform immunotherapy developmentCAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the titles and times of its presentations at the upcoming 35th Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2020) taking place virtually November 9th – 14th.The following posters will be available on Monday, November 9 at 8 a.m. ET:Abstract Number: 390Title: Emerging safety and activity data...

GenMark Diagnostics to Report Third Quarter 2020 Financial Results on October 28, 2020

Written by Customer Service on October 14, 2020. Posted in Public Companies.

CARLSBAD, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, October 28, 2020. Management will hold a conference call to review the company’s financial performance starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. The conference call will be concurrently webcast.The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 2955234 approximately ten minutes prior to the start time.ABOUT GENMARK DIAGNOSTICSGenMark...

Nano One Announces $10 Million Equity Offering Co-Led by Eight Capital and Gravitas Securities

Written by Customer Service on October 14, 2020. Posted in Public Companies.

VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) — (TSX-V: NNO) (OTC-Nasdaq Intl Designation: NNOMF) (Frankfurt: LBMB). Nano One Materials Corp. (“Nano One” or the “Company”) is pleased to announce a proposed offering of up to 3,676,500 units of the Company (the “Units”) at an offering price of $2.72 per Unit (the “Issue Price”), for aggregate gross proceeds of up to $10,000,080 (the “Offering”). The Units will be offered on a best efforts basis by Eight Capital and Gravitas Securities Inc., as co-lead agents and joint bookrunners (the “Agents”), pursuant to a short form prospectus filed today in each of the Provinces of Canada, other than Quebec (the “Prospectus”).Each Unit will be comprised of one common share in the capital of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (each whole...

PacWest Bancorp Announces Results for the Third Quarter 2020

Written by Customer Service on October 14, 2020. Posted in Earnings Releases And Operating Results.

Significant ItemsNet Earnings of $45.5 Million, or $0.38 Per Diluted ShareStrong Pre-Provision, Pre-Tax Net Revenue (“PPNR”) of $156.2 MillionStrong Capital Position – CET1 Ratio up 49 Basis Points to 10.46%Core Deposits Up $1.6 Billion or 10% in Q3; Represents 88% of Total DepositsTax Equivalent Net Interest Margin of 3.90% Compared to 4.20% in Q2Cost of Average Total Deposits Decreased to 17 Basis PointsLOS ANGELES, Oct. 14, 2020 (GLOBE NEWSWIRE) — PacWest Bancorp (Nasdaq: PACW) today announced net earnings for the third quarter of 2020 of $45.5 million, or $0.38 per diluted share, compared to net earnings for the second quarter of 2020 of $33.2 million, or $0.28 per diluted share. The increase in net earnings for the third quarter was due primarily to a $23 million decrease in the provision for credit losses.Matt Wagner, President...

Freehold Royalties Ltd. Declares Dividend for October 2020

Written by Customer Service on October 14, 2020. Posted in Dividend Reports And Estimates.

CALGARY, Alberta, Oct. 14, 2020 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold) (TSX:FRU) announces that its Board of Directors has declared a dividend of Cdn. $0.015 per common share to be paid on November 16, 2020 to shareholders of record on October 31, 2020.These dividends are designated as “eligible dividends” for Canadian income tax purposes.Freehold’s focus is on acquiring and managing oil and gas royalties. Freehold’s common shares trade on the Toronto Stock Exchange in Canada under the symbol FRU.For further information, contact:

Genmab Announces Data to be Presented at SITC 35th Anniversary Annual Meeting

Written by Customer Service on October 14, 2020. Posted in Public Companies.

Media ReleasePreliminary data from Phase 1/2a trial of DuoBody®-PD-L1x4-1BB (GEN1046) in patients with advanced solid tumors accepted for e-poster presentationPre-clinical data for DuoBody-PD-L1x4-1BB (GEN1046), tisotumab vedotin and DuoBody-CD3x5T4 will also be presentedGenmab A/S (Nasdaq: GMAB) announced today that multiple abstracts for Genmab programs were accepted for presentation at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting. Accepted abstracts include preliminary data from the first-in-human Phase 1/2a study of DuoBody®-PD-L1x4-1BB (GEN1046), a bispecific antibody in joint development with BioNTech, in patients with advanced solid tumors, which was accepted for e-poster presentation. All abstracts are scheduled to be available on the SITC website on November 9, 2020.“We are pleased that...

Boku Partners with Digi to launch mobile identity services in Malaysia

Written by Customer Service on October 14, 2020. Posted in Public Companies.

LONDON, Oct. 14, 2020 (GLOBE NEWSWIRE) — Boku Inc., (AIM: BOKU), the world’s leading provider of mobile payment and identity solutions, and Malaysian mobile connectivity and internet services provider Digi Telecommunications Sdn Bhd, today announced that they have signed a partnership contract to protect mobile users against cyber-hacks, account takeover attacks, SIM swap attacks, and other forms of digital fraud.Digi is the first mobile service provider in Malaysia to partner with Boku to launch mobile identity products that proactively protect its customers from numerous cyberthreats. There is a growing demand for mobile identity authentication services in Malaysia as more companies continue to realize the necessity of advanced multi-factor authentication solutions in the wake of increased incidences of digital fraud.Digital...

Day: October 14, 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice